Arcutis Biotherapeutics, Inc. Common Stock (ARQT)
Arcutis Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing dermatology and inflammatory disease treatments. Founded to innovate within the skin disease space, it emphasizes targeted therapies for conditions such as psoriasis, atopic dermatitis, and other inflammatory skin disorders.
Company News
Arcutis Biotherapeutics granted 35,500 restricted stock units to four newly hired employees under their 2022 Inducement Plan, with units vesting over four years.
Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.
Arcutis Biotherapeutics' Zoryve cream 0.15% has been approved by the FDA for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged six years and older. The approval is based on positive data from two phase III studies, and the company plans to make the drug widely available by the end of July.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) reported its first-quarter financial results after the bell Tuesday. Here's a look at the highlights. The Details: Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of $14.68 million by 237.66% and represented 1,680% increase over sales of $2.78 million from ...Full story available on Benzinga.com
The company released phase 3 trial results for an atopic dermatitis cream.